Correction: Enhanced Cytotoxic Effects of 5-Fluorouracil by Olaparib

Overview

This correction addresses an image duplication in the original article regarding the effects of Olaparib on colorectal cancer cells with mismatch repair deficiency. The quantitative analysis remains unaffected by this correction, and the specific image affected was the HCT116 5-FU 5 µM + Olaparib 5 µM condition.

Background

Mismatch repair deficiency in colorectal cancer is associated with distinct treatment responses and prognostic outcomes, as supported by various studies. Understanding the interactions between therapies, such as 5-Fluorouracil and Olaparib, is crucial for optimizing treatment strategies in this patient population.

Data Highlights

No numerical data is provided in the correction, which emphasizes the focus on correcting the image rather than altering the quantitative analysis.

Key Findings

• An image duplication was identified in the original publication.
• The quantitative analysis was performed on original sample slides, ensuring the results remain valid.
• The correction does not alter the reported results or conclusions of the study.

Clinical Implications

Clinicians should be aware of the importance of accurate representation of data in research publications. The findings related to mismatch repair deficiency continue to inform treatment decisions in colorectal cancer.

Conclusion

The correction clarifies an error in the original article without impacting the study's conclusions.

Related Resources & Content

1. BMC Cancer, 2021 -- Correction: Enhanced Cytotoxic Effects of 5-Fluorouracil by Olaparib
2. The ASCO Post — Adding Adjuvant Oxaliplatin to Fluoropyrimidine May Be of Benefit in Deficient Mismatch Repair Colon Cancer
3. The ASCO Post — Impact of Deficient DNA Mismatch Repair on Disease-Free Survival in Stage III Colon Cancer
4. The ASCO Post — Mismatch Repair Deficiency Predicts Benefit With Pembrolizumab in Colorectal Cancer
5. The ASCO Post — Mismatch Repair Deficiency Predicts Benefit With Pembrolizumab in Colorectal Cancer
6. Adding Adjuvant Oxaliplatin to Fluoropyrimidine May Be of Benefit in Deficient Mismatch Repair Colon Cancer
7. Impact of Deficient DNA Mismatch Repair on Disease-Free Survival in Stage III Colon Cancer
8. Mismatch Repair Deficiency Predicts Benefit With Pembrolizumab in Colorectal Cancer
9. FDA approves nivolumab with ipilimumab for unresectable or metastatic MSI-H or dMMR colorectal cancer
10. Adjuvant Use of Atezolizumab Plus Chemotherapy in DNA Mismatch Repair–Deficient Colon Cancer
11. Olaparib with or without bevacizumab versus bevacizumab plus a fluoropyrimidine as maintenance therapy in advanced colorectal cancer: The randomized phase 3 LYNK-003 study - ScienceDirect